Details for Patent: 11,191,766

Which drugs does patent 11,191,766 protect, and when does it expire?

Patent 11,191,766 protects VITRAKVI and is included in one NDA.

This patent has fifty-seven patent family members in twenty-eight countries.

Summary for Patent: 11,191,766

Title:	Methods of treating pediatric cancers
Abstract:	A method of treating a pediatric cancer in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, or a pharmaceutically acceptable salt thereof, or a combination thereof.
Inventor(s):	Cox Michael, Nanda Nisha
Assignee:	Loxo Oncology, Inc.
Application Number:	US16739845
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 11,191,766

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes						METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT

International Family Members for US Patent 11,191,766

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108090
Australia	2017246547
Australia	2017246554
Brazil	112018070017